Efficacy of current antiemetic treatments for preventing delayed chemotherapy-induced nausea and vomiting: A meta-analysis of randomized controlled trials

Clinical Research and Regulatory Affairs

Volumn 21, Issue 3-4, 2004, Pages 191-212

  Jia, Qing Huang ^a   Ge, Fan Zheng ^a   Chan, Godfrey C F ^a   Karlberg, Johan ^a   Shiu, Kum Lam ^a   Wong, Benjamin C Y ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

5 HT3 receptor antagonist; Antiemetic; Chemotherapy; Dexamethasone; Meta analysis; Metoclopramide

Indexed keywords

ANTHRACYCLINE; ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTOSTATIC AGENT; DEXAMETHASONE; DOLASETRON MESILATE; DOMPERIDONE; DOXORUBICIN; EPIRUBICIN; GRANISETRON; IFOSFAMIDE; METOCLOPRAMIDE; ONDANSETRON; PROCHLORPERAZINE; SEROTONIN 3 ANTAGONIST; TROPISETRON;

ARTICLE; CANCER CHEMOTHERAPY; CLINICAL TRIAL; CONFIDENCE INTERVAL; DRUG EFFICACY; HUMAN; META ANALYSIS; NAUSEA AND VOMITING; PROPHYLAXIS; RISK ASSESSMENT;

EID: 15444379255     PISSN: 10601333     EISSN: None     Source Type: Journal    
DOI: 10.1081/CRP-200049997     Document Type: Article

References (43)

1. NCCN Practice Guidelines in Oncology, Version 2, National Comprehensive Cancer Network, 2003.
2. Ihbe-Heffinger A, Ehlken B, Bernard R, Berger K, Peschel C, Eichler HG, Deuson R, Thodtmann J, Lordick F. The impact of delayed chemotherapy-induced nausea and vomiting on patients, health resource utilization and costs in German cancer centers. Ann Oncol Mar 2004; 15(3):526-536.
3. del Giglio A, Soares HP, Caparroz C, Castro PC. Granisetron is equivalent to ondansetron for prophylaxis of chemotherapy-induced nausea and vomiting: results of a meta-analysis of randomized controlled trials. Cancer Dec 1, 2000; 89(11):2301-2308.
4. 3 receptor antagonists to conventional anti-emetics in the prophylaxis of acute chemotherapy-induced vomiting. Eur J Cancer Jan 1997; 33(1):66-74.
5. Fauser AA, Fellhauer M, Hoffmann M, Link H, Schlimok G, Gralla RJ. Guidelines for anti-emetic therapy: acute emesis. Eur J Cancer Mar 1999; 35(3):361-370.
6. Olver I, Paska W, Depierre A, Seitz JF, Stewart DJ, Goedhals L, McQuade B, McRae J, Wilkinson JR. A multicentre, double-blind study comparing placebo, ondansetron and ondansetron plus dexamethasone for the control of cisplatin-induced delayed emesis. Ondansetron Delayed Emesis Study Group. Ann Oncol Nov 1996; 7(9):945-952.
7. Gralla RJ, Osoba D, Kris MG, Kirkbride P, Hesketh PJ, Chinnery LW, Clark-Snow R, Gill DP, Groshen S, Grunberg S, Koeller JM, Morrow GR, Perez EA, Silber JH, Pfister for the American Society of Clinical Oncology DG. Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. J Clin Oncol 1999; 17(9):2971-2994.
8. Hulstaert F, Van Belle S, Bleiberg H, Canon JL, Dewitte M, Buyse M, Keyser DeP, Westelinck KJ. Optimal combination therapy with tropisetron in 445 patients with incomplete control of chemotherapy-induced nausea and vomiting. J Clin Oncol Nov 1994; 12(11):2439-2446.
9. Kris MG, Gralla RJ, Tyson LB, Clark RA, Cirrincione C, Groshen S. Controlling delayed vomiting: double-blind, randomized trial comparing placebo, dexamethasone alone, and metoclopramide plus dexamethasone in patients receiving cisplatin. J Clin Oncol Jan 1989; 7(1):108-114.
10. 3-receptor antagonists in the control of delayed-onset emesis. Anticancer Res 2003; 23:2773-2782.
11. Rusthoven J, Obrien BJ, Rocchi A. Ondansetron versus metoclopramide in the prevention of chemotherapy-induced nausea and vomiting - a meta-analysis. Int J Oncol 1992; 1(4):443-450.
12. Tan M. Granisetron: new insights into its use for the treatment of chemotherapy-induced nausea and vomiting. Expert Opin Pharmacother Sep 2003; 4(9):1563-1571.
13. Kris MG, Tyson LB, Clark RA, Gralla RJ. Oral ondansetron for the control of delayed emesis after cisplatin. Report of a phase II study and a review of completed trials to manage delayed emesis. Cancer Aug 15, 1992; 70(4 suppl):1012-1016 Review.
14. The Italian Group for Antiemetic Research. Dexamethasone, granisetron, or both for the prevention of nausea and vomiting during chemotherapy for cancer. NEJM 1995; 332:1-5.
15. Goedhals L, Heron JF, Kleisbauer JP, Pagani O, Sessa C. Control of delayed nausea and vomiting with granisetron plus dexamethasone or dexamethasone alone in patients receiving highly emetogenic chemotherapy: a double-blind, placebo-controlled, comparative study. Ann Oncol Jun 1998; 9(6):661-666.
16. Jadad A. Randomized Controlled Trials. London: BMJ Books, 1998.
17. Hesketh PJ, Gralla J, du Bois A, Tonato M. Methodology of antiemetic trials: response assessment, evaluation of new agents and definition of chemotherapy emetogenicity. Support Care Cancer 1998; 6:221-227.
18. Hesketh PJ, Kris MG, Grunberg SM, Beck T, Hainsworth JD, Harker G, Aapro MS, Gandara D, Lindley CM. Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol Jan 1997; 15(1):103-109.
19. The Italian Group for Antiemetic Research. Dexamethasone alone or in combination with ondansetron for the prevention of delayed nausea and vomiting induced by chemotherapy. N Engl J Med May 25, 2000; 342(21):1554-1559.
20. Latreille J, Pater J, Johnston D, Laberge F, Stewart D, Rusthoven J, Hoskins P, Findlay B, McMurtrie E, Yelle L, Williams C, Walde D, Ernst S, Dhaliwal H, Warr D, Shepherd F, Mee D, Nishimura L, Osoba D, Zee B. Use of dexamethasone and granisetron in the control of delayed emesis for patients who receive highly emetogenic chemotherapy. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol Mar 1998; 16(3):1174-1178.
21. Sorbe BG, Berglind AM, Andersson H, Boman K, Hogberg T, Hallgren M, Schmidt M. A study evaluating the efficacy and tolerability of tropisetron in combination with dexamethasone in the prevention of delayed platinum-induced nausea and emesis. Cancer Sep 1, 1998; 83(5):1022-1032.
22. Tsukada H, Hirose T, Yokoyama A, Kurita Y. Randomised comparison of ondansetron plus dexamethasone with dexamethasone alone for the control of delayed cisplatin-induced emesis. Eur J Cancer Dec 2001; 37(18):2398-2404.
23. The Italian Group for Antiemetic Research. Ondansetron versus metoclopramide, both combined with dexamethasone, in the prevention of cisplatin-induced delayed emesis. J Clin Oncol 1997; 15(1):124-130.
24. Aapro MS, Thuerlimann B, Sessa C, de Pree C, Bernhard J, Maibach on behalf of the Swiss Group for Clinical Cancer Research (SAKK) R. A randomized double-blind trial to compare the clinical efficacy of granisetron with metoclopramide, both combined with dexamethasone in the prophylaxis of chemotherapy-induced delayed emesis. Ann Oncol 2003; 14:291-297.
25. Jara C, Hernandez M, Alonso C, Fernandez A, Gomez-Aldaravi JL, Mayordomo JI. Dexamethasone with oral granisetron or metoclopramide in preventing chemotherapy-induced delayed emesis. A randomized, double-blind trial. Proc Am Soc Clin Oncol 1999; 18, abstract2289.
26. 3 receptor antagonists in patients receiving moderately or highly emetogenic chemotherapy. Curr Oncol 2000; 8(2):69-76.
27. Ioannidis JP, Hesketh PJ, Lau J. Contribution of dexamethasone to control of chemotherapy-induced nausea and vomiting: a meta-analysis of randomized evidence. J Clin Oncol Oct 1, 2000; 18(19):3409-3422.
28. Kovac AL. Benefits and risks of newer treatments for chemotherapy-induced and postoperative nausea and vomiting. Drug Saf 2003; 26(4):227-259.
29. ESMO Guidelines Task Force for Prohphylaxis of Chemotherapy-Induced Nausea and Vomiting. April 2002. www.esmo.org/reference/reference_guidelines. htm.
30. Italian Group for Antiemetic Research. Transferability to clinical practice of the results of controlled clinical trials: the case of antiemetic prophylactic treatment for cancer chemotherapy-induced nausea and vomiting. Ann Oncol 1998; 9(7):759-765.
31. Dranitsaris G, Leung P, Warr D. Implementing evidence based antiemetic guidelines in the oncology setting: results of a 4-month prospective intervention study. Support Care Cancer Nov 2001; 9(8):611-618.
32. Debrix I, Flahault A, Becker A, Schwartz L, Kanfer A, Milleron B. Impact of guidelines implemented in a Paris university hospital: application to the use of antiemetics by cancer patients. Br J Clin Pharmacol Oct 1999; 48(4):616-622.
33. Roila F, Ballatori E. The efficacy and cost-effectiveness of various antiemetic regimens. Curr Opin Oncol Jul 1998; 10(4):310-315.
34. 3-receptor antagonists and the cytochrome P450 system: clinical implications. Cancer J Sep-Oct 2002; 8(5):405-414.
35. MacDonald TM. Metoclopramide, domperidone and dopamine in man: actions and interactions. Eur J Clin Pharmacol 1991; 40(3):225-230.
36. Janes RJ, Muhonen T, Karjalainen UP, Wiklund T. Urinary 5-hydroxyindoleacetic acid (5-HIAA) excretion during multiple-day high-dose chemotherapy. Eur J Cancer Jan 1998; 34(1):196-198.
37. Cubeddu LX, Hoffmann IS. Participation of serotonin on early and delayed emesis induced by initial and subsequent cycles of cisplatinum-based chemotherapy, effects of antiemetics. J Clin Pharmacol Aug 1993; 33(8):691-697.
38. Wilder-Smith OH, Borgeat A, Chappuis P, Fathi M, Forni M. Urinary serotonin metabolite excretion during cisplatin chemotherapy. Cancer Oct 1, 1993; 72(7):2239-2241.
39. Castejon AM, Paez X, Hernandez L, Cubeddu LX. Use of intravenous microdialysis to monitor changes in serotonin release and metabolism induced by cisplatin in cancer patients: comparative effects of granisetron and ondansetron. J Pharmacol Exp Ther 1999; 291:960-966.
40. Roila F, Donati D, Tamberi S, Margutti G. Delayed emesis: incidence, pattern, prognostic factors and optimal treatment. Support Care Cancer 2002; 10:88-95.
41. Pater J, Slamet L, Zee B, Osoba D, Warr D, Rusthoven J. Inconsistency of prognostic factors for post-chemotherapy nausea and vomiting. Support Care Cancer May 1994; 2(3):161-166.
42. Olver IN, Simon RM, Aisner J. Antiemetic studies: a methodological discussion. Cancer Treat Rep May 1986; 70(5):555-563.
43. Aapro M. Methodological issues in antiemetic studies. Invest New Drugs Nov 1993; 11(4):243-253.